Published in World J Gastroenterol on February 21, 2014
Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology (2015) 1.67
Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol (2014) 1.05
Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. Biomed Res Int (2015) 0.93
Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One (2015) 0.88
Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS One (2015) 0.86
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Dig Dis Sci (2016) 0.84
Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol (2015) 0.83
Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLoS One (2015) 0.82
Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. J Clin Transl Hepatol (2015) 0.82
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol (2015) 0.81
Clinical advances in pediatric nonalcoholic fatty liver disease. Hepatology (2016) 0.81
Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.80
Insulin resistance in the liver: deficiency or excess of insulin? Cell Cycle (2014) 0.80
Arrhythmia risk in liver cirrhosis. World J Hepatol (2015) 0.79
Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease? Int J Mol Sci (2015) 0.79
An Evolutionary Perspective of Nutrition and Inflammation as Mechanisms of Cardiovascular Disease. Int J Evol Biol (2015) 0.78
Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population. J Am Heart Assoc (2015) 0.78
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol (2016) 0.77
Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol (2015) 0.77
Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol (2016) 0.77
Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. World J Gastroenterol (2015) 0.76
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight. Int J Mol Sci (2016) 0.76
Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med Sci Monit (2014) 0.76
Coffee consumption and NAFLD: a community based study on 1223 subjects. BMC Res Notes (2015) 0.76
Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int J Mol Sci (2016) 0.76
Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J (2016) 0.75
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep (2016) 0.75
Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study. PLoS One (2016) 0.75
Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin. Int J Mol Sci (2016) 0.75
Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.75
Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. Cureus (2017) 0.75
Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators. Can J Gastroenterol Hepatol (2017) 0.75
Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test. Indian J Med Res (2016) 0.75
Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol (2016) 0.75
Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep (2017) 0.75
Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. Oncotarget (2017) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med (1999) 8.14
n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med (2013) 7.24
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med (2010) 7.12
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA (2007) 5.89
Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol (2006) 5.39
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology (2005) 4.86
Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol (2008) 4.72
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation (1994) 4.32
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia (2012) 3.70
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ (2011) 3.69
Vitamin D receptor as an intestinal bile acid sensor. Science (2002) 3.64
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol (2006) 3.62
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut (2012) 3.56
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation (1991) 3.25
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol (2005) 3.15
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology (2010) 3.03
Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis (2006) 2.95
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology (2008) 2.70
Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology (2008) 2.63
Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol (2007) 2.61
Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol (2008) 2.61
Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol (2007) 2.45
Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (2012) 2.44
Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut (2011) 2.38
Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology (2013) 2.28
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr (2012) 2.23
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut (2004) 2.15
Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol (2012) 2.15
Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol (2010) 2.12
Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol (2012) 2.11
Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study. Angiology (2013) 2.11
Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm (2009) 2.09
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care (2007) 2.09
Positive feedback sharpens the anaphase switch. Nature (2008) 2.07
Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology (2008) 2.07
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol (2010) 2.06
Atrial fibrillation. Lancet (2011) 2.05
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care (2006) 2.04
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology (2013) 2.03
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia (2012) 1.98
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology (2009) 1.97
Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis (2006) 1.96
Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology (2013) 1.94
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology (2011) 1.85
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol (2012) 1.83
Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care (2004) 1.79
Prognostic value of absence or presence of coronary artery disease determined by 64-slice computed tomography coronary angiography a systematic review and meta-analysis. Int J Cardiovasc Imaging (2010) 1.77
From NAFLD in clinical practice to answers from guidelines. J Hepatol (2013) 1.76
Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol (2009) 1.75
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J (2012) 1.73
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol (2012) 1.71
Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol (2008) 1.71
Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol (2012) 1.70
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol (2011) 1.69
Liver: an alarm for the heart? Liver Int (2007) 1.59
Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology (2010) 1.58
Coronary heart disease prevention: nutrients, foods, and dietary patterns. Clin Chim Acta (2011) 1.52
Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clin Chem Lab Med (2010) 1.52
Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2012) 1.52
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol (2013) 1.49
Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol (2013) 1.48
Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut (2011) 1.46
Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology (2010) 1.45
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab (2013) 1.44
Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging. Circ J (2012) 1.42
The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars (2008) 1.42
Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study. Atherosclerosis (2012) 1.40
Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol (2011) 1.36
Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol (2011) 1.32
Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs (2004) 1.30
Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2013) 1.29
Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost (2012) 1.28
Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol (2006) 1.27
Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology (2003) 1.24
Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2013) 1.23
Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology (2010) 1.22
Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J (2010) 1.21
Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol (2011) 1.21
Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci (2009) 1.19
Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care (2011) 1.19